Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
November 7, 2019
RegMed Investors’ (RMi) pre-open: will they or won’t they …deal
November 6, 2019
Regenerative Medicine Earnings Scorecard - Q3/19 - to date
November 6, 2019
RegMed Investors’ (RMi) closing bell: Framing the main takeaway … pricing, volume and volatility!
November 4, 2019
RegMed Investors’ (RMi) closing bell: the market rips, the sector dips on the second session of November
October 31, 2019
RegMed Investors’ (RMi) closing bell: The sector risks are still to the downside
October 30, 2019
RegMed Investors’ (RMi) closing bell: strength came from trading the downside
October 29, 2019
RegMed Investors’ (RMi) closing bell: hard to grow, easy to go as the sector flip flops with an Advance/Decline (A/D) line downslide
October 29, 2019
RegMed Investors’ (RMi) pre-open: futures retreat, after Monday’s upside run; strength to be sold into?
October 28, 2019
RegMed Investors’ (RMi) closing bell: indexes set new records
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors